In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants | Zendy

Marie-No�lle Brunelle | Zendy; Julie Lucifora | Zendy; Johan Neyts | Zendy; Stéphanie Villet | Zendy; Antonı́n Holý | Zendy; C. Trépo | Zendy; Fabien Zoulim | Zendy

Open Access

In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants

Author(s) -

Marie-No�lle Brunelle,

Julie Lucifora,

Johan Neyts,

Stéphanie Villet,

Antonı́n Holý,

C. Trépo,

Fabien Zoulim

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01440-06

Subject(s) - adefovir , lamivudine , entecavir , pyrimidine , hepatitis b virus , virology , in vitro , mutant , multiple drug resistance , chemistry , biology , drug resistance , virus , stereochemistry , microbiology and biotechnology , biochemistry , gene

The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research